Stimuli-responsive biopolymer hydrogel formulations for reducing menstrual fluid stain visibility

Overview

Aegelys is developing biopolymer hydrogel formulations designed to reduce the visibility of menstrual fluid stains. The technology uses selective molecular binding domains that form in response to physiological and environmental stimuli. When the formulation contacts menstrual fluid, it binds red blood cells, hemoglobin, and other colored components, preventing them from passing into clothing or feminine hygiene products. This physiological responsiveness means the active binding behavior occurs only when needed, potentially providing stain protection without the burden of continuous activity.

The proposed products are intended for incorporation into absorbent articles such as feminine hygiene products and clothing, with a focus on prevention and discreet protection. The polymers are described as GRAS (generally recognized as safe), inexpensive to produce, stable, and compatible with fabrics and absorbent materials—attributes that support eventual scale-up and integration into manufacturing lines.

Technical specifications

Mechanism of action:

• Selective binding domains form in response to physiological and environmental cues.
• Targets include red blood cells, hemoglobin, and other colored components in menstrual fluid.
• Binding and capture prevent transfer of colored components into adjacent fabrics or hygiene products.

Key features:

• GRAS biopolymer basis for safety and regulatory familiarity.
• Room-temperature, 37°C, and 65°C stability are planned targets for formulation optimization.
• Designed for direct incorporation into absorbents or as a powder to be integrated into feminine hygiene products or clothing.

Preliminary evidence:

• Quantitative capture demonstrated with BSA/Lecithin/cholate coated polyethylene micro- and nano-particles.
• Significant capture of small molecules observed, supporting the feasibility of binding colored components.

Technology readiness level

The technology is at an early research and development stage. The fundamental hypothesis has been established and preliminary data support the capture mechanism, but the active ingredients have not yet been optimized against menstrual fluid components. Planned validation steps include constructing a library of active ingredients, characterizing and optimizing binding to red blood cells and hemoglobin, formulation stability and responsiveness testing, process development and scale-up, and deployment for future field trials to assess safety and efficacy in relevant human models. These studies are necessary to advance from proof-of-concept toward a prototype and eventual commercial application.